Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Kairos Pharma Q3 2026 Results: Net Loss of $1.98M, Loss Widens

Kairos Pharma, Ltd. reported a net loss of $5.03 million for the nine months ended September 30, 2026, compared to a $4.08 million loss in the prior year period. The company remains in the development stage with no revenue, and its cash position decreased to $3.13 million as of September 30, 2026, from $4.49 million at year-end 2025.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-2.0-1.4
EPS (diluted, $ a share)$-0.59$-0.48

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NYSE: KAPA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Kairos Pharma, LTD.: key numbers

Share price
$0.4069Close, Nov 16
Market cap
$1.91M
Shares outstanding
4.69MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Kairos Pharma, LTD.

All →
11:51 AM ET 8-K
Capital Raise

Kairos Pharma Capital Raise

Kairos Pharma, Ltd. entered into a third amendment to its existing equity line of credit (ELOC) purchase agreement with Helena Global Investment Opportunities I Ltd. The amendment extends the company's option to use the ELOC for an additional year until December 31, 2028, and follows previous amendments that adjusted the purchase price to 97% of VWAP and shortened the pricing period.

Counterparty
Helena Global Investment Opportunities I Ltd.
Term
through Dec 2028
7:30 AM ET 8-K
Clinical Trial Data

Kairos Pharma Clinical Trial Data

Kairos Pharma reported positive interim efficacy data from its Phase 2 trial of ENV-105 (carotuximab) in combination with apalutamide for metastatic castration-resistant prostate cancer. The combination therapy demonstrated a statistically significant median progression-free survival of 17.7 months compared to 2 months for apalutamide alone (P=0.0008). Based on these results, the company has modified the trial protocol to enroll patients earlier in the disease progression and targets trial completion by Q4 2027.

4:01 PM ET 8-K
Investor Presentation

Kairos Pharma Investor Presentation

Kairos Pharma, Ltd. issued a new investor presentation to be presented by CEO John Yu at the H.C. Wainwright 28th Annual Global Investment Conference in New York. The presentation provides an update on the company's clinical programs and activities.

Counterparty
H.C. Wainwright 28th Annual Global Investment Conference

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.